Compare Royal Bank of Canada (RY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs GeneDx Holdings Corp — how do they compare? Royal Bank of Canada trades at $190.84 (market cap $262.99B), while GeneDx Holdings Corp trades at $67.82 (market cap $2.02B). The key difference: Royal Bank of Canada is far larger — about 130.2× GeneDx Holdings Corp's market cap, and Royal Bank of Canada pays a 2.66% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Bank of Canada for 47 Days and GeneDx Holdings Corp for 19 Days on average.
| RY | WGS | |
|---|---|---|
Market Cap | $262.99B | $2.02B |
Volume | 1,016,377 | 734,640 |
Sector | Financials | Health |
52-Week High | $217.87 | $167.51 |
52-Week Low | $143.64 | $34.51 |
Typical Hold Time | 47 Days | 19 Days |
Enterprise Value | $730.11B | $2.05B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $190.31, down 0.48% with a bearish technical signal despite strong fundamentals. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.07 exceeding expectations. Revenue growth accelerated to $66.53B in 2025 with a 32.01% net margin, while analyst consensus shows 43% buy ratings amid mixed sentiment.
RY presents a valuation disconnect with solid profitability (17.2% ROE) against bearish technicals. Investment opportunity lies in consistent earnings growth and dividend yield, though risks include stretched valuations and negative cash flow trends. The stock faces headwinds from technical indicators but maintains fundamental strength for long-term investors.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
